Tagged with UK

UK The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as its third largest export destination. However, with the Japanese government having previously expressed concern about uncertainties arising from the Brexit…

Saudi Arabia The top 10 pharma companies in Saudi Arabia ranked by sales value in USD millions MAT Q1 2019. These top 10 corporations account for 50 percent of total sales in the USD 8.2 billion Saudi pharma market. Global giants Pfizer, Sanofi, and Novartis make up the top three spots, but…

UK US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research Centre’ by 2025.   Having announced that the hub would be built in 2017, one year after the UK’s vote…

UK Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national innovation forwards.   With the upheaval of recent months, businesses up and down the UK have been forced to adapt…

Japan Japan’s pharma market is one of the world’s biggest, with a value of around USD 95 billion, according to figures from the country’s Ministry of Health, Labour and Welfare (MHLW). Japanese firms have a particularly strong standing in their home market, making up six of the country’s top ten pharma…

Roundup Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access developments.   Coronavirus leading to ICU drug shortages In the UK the coronavirus pandemic is leading to shortages of drugs…

Coronavirus The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19); an unprecedented agreement that shows the scale of the challenge facing the global biopharmaceutical industry and possibly provides the world’s…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Czech Republic The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical trials. However, a decline in the number of clinical trials in recent years means that Czech stakeholders are looking to…

UK With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life science investment destinations and multinational pharma firms including Novartis are already taking note.   “Tangible Opportunity” In February 2020, the…

UK Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get Brexit Done”.   The UK now enters an 11-month transition period to disentangle political and economic ties from a single…

UK  A new report from the UK BioIndustry Association (BIA) asserts that the UK biotech industry is booming, despite Brexit uncertainties. Financing raised by UK biotechs in 2019 was down on the record year of 2018, but up on 2016 and 2017. Made with Visme Infographic Maker   A longer term perspective…